May 30th, 2023

A full text version of this article is available.
To access article obtain online access here or login
Mifepristone Followed by High-Dose Oxytocin Drip for Second-Trimester Abortion: A Randomized, Double-Blind, Placebo-Controlled, Pilot Study
Authors:  Assaf Ben-Meir, M.D., Yair Erez, M.D., Tomer Feigenberg, M.D., Yaron Hamani, M.D., Neri Laufer, M.D., and Nathan Rojansky, M.D.
  OBJECTIVE: To study the effect of mifepristone for priming and induction of second-trimester abortion in conjunction with a high-concentration oxytocin drip.

STUDY DESIGN: Prospective, randomized, placebo-controlled, pilot study. Thirty patients with 14-25 weeks‘ gestational age abortion received either 600 mg of mifepristone or placebo in 3 identical capsules followed, 48 hours later, by a high-
concentration oxytocin drip (HCOD).

RESULTS: The mifepristone group showed significantly higher success rates as compared to the placebo group (92.3% vs. 52.9%, p<0.05). The time interval to abortion (from beginning of HCOD) was also significantly shorter in the mifepristone group as compared to the placebo group (11.3±6.0 hours vs. 17.6±6.5 hours, p<0.05). Probability of success as calculated by the Kaplan-Meier method was found to be highly significant (log rank test p=0.001).

CONCLUSION: Our results suggest that mifepristone is very effective for priming and induction of second-trimester abortion and shortens significantly the time interval to evacuation following HCOD. (J Reprod Med 2009;54:511-516)
Keywords:  induced abortion, mifepristone, missed abortion, oxytocin
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from